#USA #Phoenix #NSCLC #iOnctura #roginolisib

iOnctura's Late-Breaking Presentation at SITC 2026

On November 6, 2026, iOnctura will unveil significant results from its ongoing PULMO-01 clinical trial examining roginolisib as a treatment for patients facing immunotherapy-resistant non-small cell lung cancer (NSCLC) at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Phoenix, Arizona.

Overview of the PULMO-01 Study

The late-breaking presentation will include data on roginolisib, a leading-edge PI3Kδ inhibitor. This drug is being studied in combination with dostarlimab, potentially alongside docetaxel, specifically targeting patients whose cancer has continued to progress even after previous treatments with immune checkpoint inhibitors or combinations that included platinum-based chemotherapy.

Details of the Presentation

• - Poster Title: Roginolisib plus dostarlimab with or without docetaxel reverts immune suppression and shows clinical activity in immunotherapy-resistant non-small cell lung cancer.
• - Presentation Date: Friday, November 6, 2026
• - Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
• - Abstract Number: 1181

This presentation will address a prominent challenge in advanced NSCLC treatment: resistance to immune checkpoint inhibitors, chiefly caused by the infiltration of immunosuppressive regulatory T cells (Tregs). Roginolisib stands out for its ability to inhibit activated Tregs effectively, potentially reestablishing treatment sensitivity in NSCLC patients.

CEO Statement

Catherine Pickering, CEO at iOnctura, remarked, “The acceptance of our late-breaking poster at SITC highlights the increased interest in innovative methods to overcome immunotherapy resistance. We are eager to present data that further illuminates the effectiveness of roginolisib as a groundbreaking option for NSCLC patients.”

Insights into Roginolisib

Roginolisib is a clever non-ATP-competitive PI3Kδ inhibitor that maintains the enzyme in its inactive state by inducing an allosteric conformational shift. This unique mechanism allows for precise inhibition, reducing side effects associated with older inhibitors. The drug has exhibited promising clinical activity, supporting its potential to improve outcomes in patients with various malignancies, including eye cancer (uveal melanoma).

Currently, the safety and effectiveness of roginolisib are being investigated in multiple studies for both solid and hematological cancers. One significant study, OCULE-01, focused on uveal melanoma completed patient recruitment earlier this year. Meanwhile, the ongoing PULMO-01 study has enrolled 49 participants whose cancers had progressed on prior immunotherapy, exploring various endpoints including overall survival and changes in immune cell populations.

As iOnctura presents its findings at SITC 2026, the company's innovative approach to treating difficult-to-address cancers continues to gain momentum. With robust financial backing and a commitment to advancing precision oncology, iOnctura aims to create a meaningful impact on the lives of patients battling cancer.

By shedding light on these advancements, the medical community hopes to pave the way for more effective treatments for NSCLC and beyond.